CN103599297A - Medicament for treating qi deficiency and blood stasis-induced ischemic stroke - Google Patents
Medicament for treating qi deficiency and blood stasis-induced ischemic stroke Download PDFInfo
- Publication number
- CN103599297A CN103599297A CN201310625978.2A CN201310625978A CN103599297A CN 103599297 A CN103599297 A CN 103599297A CN 201310625978 A CN201310625978 A CN 201310625978A CN 103599297 A CN103599297 A CN 103599297A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- medicament
- herba
- blood stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating qi deficiency and blood stasis-induced ischemic stroke. The medicament is prepared from 8 parts by weight of divaricate knotweed herb, 9 parts by weight of cape jasmine, 6 parts by weight of root and stem of Daphne koreana Nakai, 9 parts by weight of lotus leaf, 6 parts by weight of all-grass of dichotomous fimbristylis, 7 parts by weight of folium artemisiae argyi, 5 parts by weight of leaf of Ligustrum sinense, 3 parts by weight of all-grass of nakedcaule groundsel, 9 parts by weight of dandelion, 2 parts by weight of dendrophthoe pentandra, 8 parts by weight of cassia bark, 3 parts by weight of rhizome of Be-gonia pedatifida Levl., 6 parts by weight of Hedyotis tenelliflora Bl., 7 parts by weight of fruit of Chinese wolfberry, 2 parts by weight of herb of tibet lancea and 3 parts by weight of sonchus brachyotus. The medicament for treating qi deficiency and blood stasis-induced ischemic stroke utilizes natural medicines and has the advantages of fast action, good curative effect and no toxic or side effect.
Description
Technical field
The present invention relates to field of medicaments, specifically, relate to a kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction.
Background technology
Apoplexy is suddenly to faint, syncope, the class disease that the distortion of commissure that occurs together, dysphonia, hemiplegia are cardinal symptom.This disease is divided into 2 types: cerebral infarction and hemorrhagic apoplexy.Cerebral infarction is the said cerebral infarction of modern medicine, due to cerebral atherosclerosis, tunica intima damage makes cerebral arteries luminal stenosis, and then because making local thrombus, many factors forms, stricture of artery is increased the weight of or entirely shut, cause cerebral tissue ischemia, anoxia, necrosis, cause a kind of cerebrovascular of delayed ischemic neurological deficits.Chinese medicine, reducing blood viscosity, improves microcirculation, and there is unique effect the aspects such as antiplatelet aggregation, significant to treatment and prevention of stroke.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction, it is to be made by weight by following bulk drugs: 3 parts of 8 parts of Herba polygoni divaricati, 9 parts of Fructus Gardeniaes, 6 parts of Radix Cochleariae officinalis grass, 9 parts, Folium Nelumbinis, 6 parts of Herba Fimbristylis dichotomae, 7 parts of Folium Artemisiae Argyis, 5 parts of ligustrum sinenses, 3 parts of Radix Semiaquilegiae, 9 parts of Herba Taraxacis, 2 parts of Dendrophthoe pentandra (L.) Miq-Loranthus pcntandrus L.s, 8 parts of Cortex Cinnamomis, 3 parts of Rhizoma begoniae pedatifidaes, 6 parts of stone maple medicines, 7 parts of Fructus Lycii, 2 parts of Herba Lanceae Tibeticae and Herba Sonchi Arvensis.
Preferably, described medicament is tablet, dispersible tablet, instant, decoction or granule.
In compositions of the present invention, Herba polygoni divaricati, Fructus Gardeniae, Radix Cochleariae officinalis grass are monarch drug; Folium Nelumbinis, Herba Fimbristylis dichotomae, Folium Artemisiae Argyi, ligustrum sinense are ministerial drug; Radix Semiaquilegiae, Herba Taraxaci, Dendrophthoe pentandra (L.) Miq-Loranthus pcntandrus L., Cortex Cinnamomi, Rhizoma begoniae pedatifidae are adjuvant drug; Stone maple medicine, Fructus Lycii, Herba Lanceae Tibeticae and Herba Sonchi Arvensis be for making medicine, various composition synergism, thereby performance optimum efficiency.
In the medicament for the treatment of Qi deficiency blood stasis type cerebral infarction of the present invention, use natural drug, so it have advantages of instant effect, good effect, has no side effect.
Accompanying drawing explanation
With reference to < < Chinese medicine voluminous dictionary > > second edition, being described as follows of some crude drug that use in the present invention:
Fig. 1 is the explanation of Herba polygoni divaricati;
Fig. 2 is the explanation of Radix Cochleariae officinalis grass;
Fig. 3 is the explanation of Herba Fimbristylis dichotomae;
Fig. 4 is the explanation of ligustrum sinense;
Fig. 5 is the explanation of Radix Semiaquilegiae;
Fig. 6 is the explanation of Dendrophthoe pentandra (L.) Miq-Loranthus pcntandrus L.;
Fig. 7 is the explanation of Rhizoma begoniae pedatifidae;
Fig. 8 is the explanation of stone maple medicine;
Fig. 9 is the explanation of Herba Lanceae Tibeticae;
Figure 10 is the explanation of Herba Sonchi Arvensis
The specific embodiment
Below the invention will be further described for the description by the specific embodiment, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various modifications or improvement, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The preparation of embodiment 1 decoction of the present invention
Get 3 grams of 8 grams of Herba polygoni divaricati, 9 grams of Fructus Gardeniaes, 6 grams of Radix Cochleariae officinalis grass, 9 grams, Folium Nelumbinis, 6 grams of Herba Fimbristylis dichotomae, 7 grams of Folium Artemisiae Argyis, 5 grams of ligustrum sinenses, 3 grams of Radix Semiaquilegiae, 9 grams of Herba Taraxacis, 2 grams of Dendrophthoe pentandra (L.) Miq-Loranthus pcntandrus L.s, 8 grams of Cortex Cinnamomis, 3 grams of Rhizoma begoniae pedatifidaes, 6 grams of stone maple medicines, 7 grams of Fructus Lycii, 2 grams of Herba Lanceae Tibeticae and Herba Sonchi Arvensis, add 8000 milliliters, water, under the condition of reflux, heat 5 hours.Filter, filtrate is decoction of the present invention.
Experimental example
Select dialectical genus Qi deficiency blood stasis type ischemic stroke patients 16 examples.Case inclusive criteria: (1) is over the adult of 18 one full year of life; (2) meet the diagnostic criteria of cerebral infarction syndrome of blood stasis due to qi deficiency: acute onset, cardinal symptom be hemiplegia, speech hold high up puckery or in silence, white, the shortness of breath and fatigue of crooked mouth and tongue, hemianesthesia, complexion Guang, slobbering be from sweating, thin white fur of tongue or greasy, deep-thready pulse or stringy and thready pulse in vain; (3) through CT or MRI, be diagnosed as the patient of cerebral infarction; (4) when morbidity is without serious disturbance of consciousness.Case exclusion standard: (1) tumor, fat, air or other mechanical plug person; Craniocerebral trauma history in (2) 1 months; Major operation or main organs biopsy history in (3) 2 weeks; (4) 3 weeks alimentary tract hemorrhage histories; (5) the abnormal person of serious hepatic and renal function; (6) platelet count is less than 10 * 10
9/ L; (7) blood glucose is less than 2.7mmo1/L or is greater than 22.3mmol/L; (8) refusal is not regularly followed up a case by regular visits to person.
With the decoction making in embodiment 1, treat, wherein one day 1 time, each oral 200 milliliters, treating 90 days is a course for the treatment of.
During drug administration, detect that all Blood of Patients are conventional, urine is conventional, stool routine examination, hepatic and renal function blood pressure and blood lipoid electrolyte, homocysteine, blood flow become, coagulation indexes, and regularly check coherent detection index.Before all patient treatments, after treatment 3d and treatment carry out after 14d function of nervous system's condition grading (the < < clinical neurologic deficit of stroke patients degree standards of grading > > passing through with reference to the 4th cerebrovascular academic conference of Chinese Medical Association) (Chinese Medical Association's the 4th cerebrovascular academic conference group in the whole nation. all kinds of cerebrovascular disease diagnosis main points [J]. Chinese Journal of Neurology, 1996, 29 (6): 379-381.), before treatment and after treatment 90d, all patient's daily life active abilities are assessed, adopt Barthel index score method to mark.Measure treatment front and back patient's hemorheology simultaneously, and content of homocysteine.
Follow up a case by regular visits to
Discharged patients regularly carries out follow-up, and the time of following up a case by regular visits to was by November 1st, 2013.Follow up a case by regular visits to content and comprise daily life active ability is assessed, the situation of medication treatment, then the vascular events of making up one's mind, and dead.
Statistical analysis
Adopt SPSS13.0 software building database and carry out statistical analysis.Measurement data adopts mean ± standard deviation to represent.The results are shown in following table.After treatment in following table, refer to that treatment is after 90 days.
Claims (2)
1. a medicament for the treatment of Qi deficiency blood stasis type cerebral infarction, it is characterized in that, it is to be made by weight by following bulk drugs: 3 parts of 8 parts of Herba polygoni divaricati, 9 parts of Fructus Gardeniaes, 6 parts of Radix Cochleariae officinalis grass, 9 parts, Folium Nelumbinis, 6 parts of Herba Fimbristylis dichotomae, 7 parts of Folium Artemisiae Argyis, 5 parts of ligustrum sinenses, 3 parts of Radix Semiaquilegiae, 9 parts of Herba Taraxacis, 2 parts of Dendrophthoe pentandra (L.) Miq-Loranthus pcntandrus L.s, 8 parts of Cortex Cinnamomis, 3 parts of Rhizoma begoniae pedatifidaes, 6 parts of stone maple medicines, 7 parts of Fructus Lycii, 2 parts of Herba Lanceae Tibeticae and Herba Sonchi Arvensis.
2. the medicament for the treatment of Qi deficiency blood stasis type cerebral infarction according to claim 1, is characterized in that, described medicament is tablet, dispersible tablet, instant, disintegrating tablet, decoction or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310625978.2A CN103599297B (en) | 2013-11-28 | 2013-11-28 | A kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310625978.2A CN103599297B (en) | 2013-11-28 | 2013-11-28 | A kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410740991.7A Division CN104383190A (en) | 2013-11-28 | 2013-11-28 | Agent for treating qi deficiency and blood stasis type ischemic stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599297A true CN103599297A (en) | 2014-02-26 |
| CN103599297B CN103599297B (en) | 2015-11-11 |
Family
ID=50117603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310625978.2A Expired - Fee Related CN103599297B (en) | 2013-11-28 | 2013-11-28 | A kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599297B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269199A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Chinese medicine preparation for treating digestive system diseases and preparation method thereof |
| CN101269198A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Pure Chinese medicine preparation for preventing and treating enteron disease and improving self phylactic power, and preparation method thereof |
-
2013
- 2013-11-28 CN CN201310625978.2A patent/CN103599297B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269199A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Chinese medicine preparation for treating digestive system diseases and preparation method thereof |
| CN101269198A (en) * | 2008-02-29 | 2008-09-24 | 西藏嘉黎县藏医院 | Pure Chinese medicine preparation for preventing and treating enteron disease and improving self phylactic power, and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599297B (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103550532B (en) | Traditional Chinese medicine (TCM) composition for treating palpitation | |
| CN104587181A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| Chen et al. | Is oral administration of Chinese herbal medicine effective and safe as an adjunctive therapy for managing diabetic foot ulcers? A systematic review and meta-analysis | |
| CN101780223B (en) | Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease | |
| CN103340936A (en) | Traditional Chinese medicine for treating primary gout | |
| CN109045191A (en) | A kind of Chinese medicine composition that treating intermenstrual bleeding disease and its application | |
| US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
| CN101347595B (en) | Chinese medicine for treating rheumatic heart of children | |
| CN103893601B (en) | A kind of medicament for the treatment of mumps | |
| CN103550702A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis | |
| CN103599297B (en) | A kind of medicament for the treatment of Qi deficiency blood stasis type cerebral infarction | |
| CN103550477B (en) | Medicament for treating herpes zoster | |
| CN104383190A (en) | Agent for treating qi deficiency and blood stasis type ischemic stroke | |
| CN104826006B (en) | A kind of pharmaceutical composition that treating lichen planus of mouth and preparation method and purposes | |
| CN103301368A (en) | Medicament for treating hyperactivity | |
| CN103356906A (en) | Traditional Chinese medicine preparation for caring insomniac and preparation method | |
| CN103816327B (en) | One treats ileac Chinese medicine composition and preparation method thereof | |
| CN103330851B (en) | Traditional Chinese medicine for treating idiopathic thrombocytopenic purpura | |
| CN103585471B (en) | Traditional Chinese medicine composition for treating thrombocytopenia | |
| CN102614373A (en) | Patch for treating aortic arch syndrome | |
| CN102614456B (en) | Preparation method of traditional Chinese medicine lotion for treating night-sweat-type ecthyma | |
| CN105194202B (en) | A kind of drug for treating liver-kidney yin deficiency premonitory apoplexy | |
| CN118001362A (en) | Traditional Chinese medicine composition, preparation and application for treating qi deficiency and blood stasis type coronary heart disease angina or PCI postoperative angina | |
| CN104940808A (en) | Traditional Chinese medicine for treatment of blood stasis and internal stagnation cerebral arteriosclerosis and preparation method thereof | |
| CN104940396B (en) | It is a kind of to reduce medicine of the Steroid-resistant nephrotic syndrome patient to Hormone refractory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151111 Termination date: 20161128 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |